Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Herbst RS, et al. Among authors: urban d. J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.1200/JCO.22.02186. Epub 2023 Jan 31. J Clin Oncol. 2023. PMID: 36720083 Free PMC article. Clinical Trial.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
Saad A, Goldstein J, Appel S, Daher S, Urban D, Onn A, Gantz-Sorotsky H, Lobachov A, Gottfried T, Spieler B, Bar J. Saad A, et al. Among authors: urban d. Thorac Cancer. 2022 Jun;13(12):1763-1771. doi: 10.1111/1759-7714.14452. Epub 2022 May 11. Thorac Cancer. 2022. PMID: 35538909 Free PMC article.
Effects of EGFR driver mutations on pathologic regression in resectable locally advanced non-small cell lung cancer treated with neoadjuvant chemoradiation and completion surgery.
Appel S, Bar J, Saad A, Marom EM, Urban D, Onn A, Gantz-Sorotsky H, Kremer RY, Ben-Nun A, Perelman M, Ofek E, Yacobi R, Daher S, Rasco A, Symon Z, Lawrence YR, Goldstein J. Appel S, et al. Among authors: urban d. Br J Radiol. 2023 Dec;96(1152):20220763. doi: 10.1259/bjr.20220763. Epub 2023 Oct 24. Br J Radiol. 2023. PMID: 37751214 Free PMC article.
Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
Bar J, Damianovich M, Hout Siloni G, Dar E, Cohen Y, Perelman M, Ben Nun A, Simansky D, Yellin A, Urban D, Onn A. Bar J, et al. Among authors: urban d. Clin Lung Cancer. 2014 Mar;15(2):159-65. doi: 10.1016/j.cllc.2013.11.005. Epub 2013 Nov 14. Clin Lung Cancer. 2014. PMID: 24370118 Clinical Trial.
292 results